Boyer Laurent, Cermolacce Michel, Dassa Daniel, Fernandez Jessica, Boucekine Mohamed, Richieri Raphaelle, Vaillant Florence, Dumas Remy, Auquier Pascal, Lancon Christophe
Aix-Marseille University, EA 3279 - Public Health, Chronic Diseases and Quality of Life - Research Unit, Marseille, France.
PLoS One. 2012;7(10):e47655. doi: 10.1371/journal.pone.0047655. Epub 2012 Oct 29.
The aim of this study was to examine the complex relationships among neurocognition, insight and nonadherence in patients with schizophrenia.
Cross-sectional study.
Diagnosis of schizophrenia according to the DSM-IV-TR criteria.
Neurocognition was assessed using a global approach that addressed memory, attention, and executive functions; insight was analyzed using the multidimensional 'Scale to assess Unawareness of Mental Disorder;' and nonadherence was measured using the multidimensional 'Medication Adherence Rating Scale.'
Structural equation modeling (SEM) was applied to examine the non-straightforward relationships among the following latent variables: neurocognition, 'awareness of positive symptoms' and 'negative symptoms', 'awareness of mental disorder' and nonadherence.
One hundred and sixty-nine patients were enrolled. The final testing model showed good fit, with normed χ(2) = 1.67, RMSEA = 0.063, CFI = 0.94, and SRMR = 0.092. The SEM revealed significant associations between (1) neurocognition and 'awareness of symptoms,' (2) 'awareness of symptoms' and 'awareness of mental disorder' and (3) 'awareness of mental disorder' and nonadherence, mainly in the 'attitude toward taking medication' dimension. In contrast, there were no significant links between neurocognition and nonadherence, neurocognition and 'awareness of mental disorder,' and 'awareness of symptoms' and nonadherence.
Our findings support the hypothesis that neurocognition influences 'awareness of symptoms,' which must be integrated into a higher level of insight (i.e., the 'awareness of mental disorder') to have an impact on nonadherence. These findings have important implications for the development of effective strategies to enhance medication adherence.
本研究旨在探讨精神分裂症患者神经认知、洞察力和不依从性之间的复杂关系。
横断面研究。
根据《精神疾病诊断与统计手册》第四版修订版(DSM-IV-TR)标准诊断为精神分裂症。
采用综合方法评估神经认知,该方法涉及记忆、注意力和执行功能;使用多维“精神障碍自知力评定量表”分析洞察力;使用多维“药物依从性评定量表”测量不依从性。
应用结构方程模型(SEM)来检验以下潜在变量之间的非直接关系:神经认知、“阳性症状自知力”和“阴性症状自知力”、“精神障碍自知力”和不依从性。
共纳入169例患者。最终测试模型显示拟合良好,标准化χ² = 1.67,RMSEA = 0.063,CFI = 0.94,SRMR = 0.092。结构方程模型揭示了(1)神经认知与“症状自知力”、(2)“症状自知力”与“精神障碍自知力”以及(3)“精神障碍自知力”与不依从性之间存在显著关联,主要体现在“服药态度”维度。相比之下,神经认知与不依从性、神经认知与“精神障碍自知力”以及“症状自知力”与不依从性之间无显著联系。
我们的研究结果支持以下假设,即神经认知影响“症状自知力”,而“症状自知力”必须整合到更高水平的洞察力(即“精神障碍自知力”)中才能对不依从性产生影响。这些发现对制定提高药物依从性的有效策略具有重要意义。